Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn’s disease after anti-tumor necrosis factor-α therapy

Nao Nishida,1,2 Masaya Sasaki,2 Mika Kurihara,2 Satomi Ichimaru,1,5 Maki Wakita,1 Shigeki Bamba,3 Akira Andoh,2 Yoshihide Fujiyama3 and Teruyoshi Amagai1,*

1Department of Food Science and Nutrition Major, Graduate School of Human Environment Sciences, Mukogawa Women’s University Graduate School, 6-46 Keibiraki-cho, Nishinomiya 663-8558, Japan
2Division of Clinical Nutrition, 3Division of Medicine and 5Division of Mucosal Immunology, Graduate School, Shiga University of Medical Science, Seta-Tsukinowa, Otsu 520-2192, Japan
3Department of Nutrition Management, Kobe City Medical Center General Hospital, 2-1-1 Minatojimanakamachi, Chuo-ku, Kobe 650-0047, Japan

(Received 17 February, 2013; Accepted 2 April, 2013; Published online 31 August, 2013)

We investigated the effects of treatment with antibodies against tumor necrosis factor (TNF)-α on energy metabolism, nutritional status, serum cytokine levels in patients with Crohn’s disease (CD). Twelve patients were enrolled. Resting energy expenditure (REE) levels were measured by indirect calorimetry. Crohn’s disease activity index (CDAI) significantly decreased after treatment with anti-TNF-α therapy. Anti-TNF-α therapy did not affect REE, but respiratory quotient (RQ) significantly increased after treatment. Serum interleukin-6 levels were significantly decreased and RQ were significantly increased in high REE (>25 kcal/kg/day) group as compared to low REE (<25 kcal/kg/day) group. In conclusion, high REE value on admission is a predictive factor for good response to treatment with anti-TNF-α antibodies in active CD patients.

Key Words: Crohn’s disease, energy metabolism, indirect calorimetry, infliximab, adalimumab

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal (GI) tract of unknown etiology but with pathogenesis likely involving genetic predisposition, alterations of gut microbiota, diet, and other environmental factors.1–3 CD is associated with symptoms such as abdominal pain and watery diarrhea, and with signs including GI bleeding and perianal fistulas. Endoscopic findings include longitudinal ulcers and mucosal bleeding. Patients often suffer from protein-energy malnutrition caused by malabsorption,4 and rates of emaciation ranging from 20–75% have been reported in patients with CD.5,6 Deficiencies of micronutrients such as zinc and selenium occur relatively frequently (25–69%), particularly in CD patients receiving long-term enteral nutrition, and nutritional support is essential in the treatment of this disease, with enteral nutrition (EN) or total parenteral nutrition (TPN) widely accepted as effective therapies for induction or maintenance of remission.7

Energy expenditure is reportedly higher in patients with CD than in healthy controls.8–10 Indeed, we previously demonstrated a marked difference in resting energy expenditure (REE) between CD patients (24.4 ± 2.4 kcal/kg/day) and healthy controls (21.3 ± 1.7 kcal/kg/day) and proposed that nutritional therapy with 25–30 kcal/ideal body weight in kg/day is optimal for patients with active CD.11 In contrast, Schneeweiss et al.11 found no marked difference in REE values between CD patients and healthy controls but reported that the respiratory quotient (RQ) was significantly lower in patients with active CD. Enteral nutrition has been reported to alter the usage of energy substrates while having no effect on energy expenditure.11

Tumor necrosis factor (TNF-α) is a pro-inflammatory cytokine expressed in the inflamed mucosa of patients with active CD. Recently, the anti-TNF-α antibodies infliximab and adalimumab have been recognized as powerful therapeutic tools for remission induction and maintenance in CD patients.12,13 Patients receiving infliximab experience decreased disease activity, with accompanying lower incidence of relapse and less frequent hospitalization.14 Further, Hanauer et al.15 reported that adalimumab was superior to placebo in inducing and maintaining remission in patients with moderate-to-severe CD.

Here, we measured changes in energy metabolism, nutritional status, and serum cytokine levels after anti-TNF-α antibody treatment of patients with active CD.

Subjects and Methods

Patients. Twelve patients, admitted with active CD to the Department of Gastroenterology at Shiga University of Medical Science Hospital between June 2011 and July 2012, were enrolled. All patients had been diagnosed with CD using radiological, histological, and clinical criteria. One patient had been treated at an outpatient clinic. Patients who had previously undergone ileostomy or colostomy were excluded.

Methods. The following values were measured before and after treatment with anti-TNF-α antibodies:

1) Anthropometrics: height (cm), weight (kg), body mass index (kg/height in meters squared), percent ideal body weight (body weight in kg × 100/height in meters squared × 22), and percent usual body weight calculated (actual body weight in kg/100/usual body weight in kg). Usual body weight was taken from a subjective global assessment sheet filled out on admission, or per patients’ reports.

2) Laboratory tests: red blood cell count (×10^6/mm³), hemoglobin (g/dl), hematocrit (%), white blood cell count ( /mm³), mean corpuscular volume (fl), total lymphocyte count ( /mm³), platelets (×10^3/mm³), C-reactive protein (mg/dl), albumin (g/dl).

doi: 10.3164/jcbn.13-18
©2013 JCBN
J. Clin. Biochem. Nutr. | September 2013 | vol. 53 | no. 2 | 122–127

*To whom correspondence should be addressed.
E-mail: amagait@nutrped.com
3) Indecies: Prognostic nutritional index (PNI) calculated as $10 \times \text{albumin (g/dl)} + 0.005 \times \text{total lymphocyte count per cubic mm}$, Crohn’s disease activity index (CDAI).

4) Energy metabolism (all measured by indirect calorimetry): REE (kcal/kg/day), RQ, carbohydrate oxidation (kcal/kg/day), and fat oxidation (kcal/kg/day).

5) Inflammatory cytokines: TNF-α (pg/dl) and interleukin-6 (IL-6) (pg/dl) were determined using commercially available ELISA kits (R&D Systems, Minneapolis, MN).

As shown in Fig. 1, subjects were categorized into two groups according to their REE (cutoff: 25 kcal/kg/day) using the values on admission.

Indirect calorimetry. REE (mREE) and non-protein respiratory quotients (np-RQ) were measured using a computed open-circuit indirect calorimeter (AE-300S; Minato Medical Science Co., Osaka, Japan). Indirect calorimetry (IC) was performed in the same ward room in the hospital after an 8-h fast. Calibration was performed prior to measurements on each patient. After resting at least 30 min, mREES were assessed in a supine position with a face mask. A pump drew ambient air through the mask at a constant rate. After equilibrating for 10 min, respiratory exchange was performed continuously over 30 min. The mREE and np-RQ data were obtained every minute. The mREE was calculated from oxygen consumption ($\text{VO}_2$) and carbon dioxide production ($\text{VCO}_2$) using the Weir’s equation.\(^{(21)}\)

$$\text{mREE} = (3.94 \times \text{VO}_2 + 1.11 \times \text{VCO}_2) \times 1.44$$

Although we were able to evaluate the rates of fat and carbohydrate oxidation, we were not able to analyze the protein oxidation rate, as urine was not collected.

**Statistical analysis.** The Wilcoxon signed rank test was used to analyze differences between two statuses (pre- and post-treatment). A $p$ value $<0.05$ was considered to be statistically significant. Results were expressed in median (25% quartile, 75% quartile).

---

**Results**

Patients’ characteristics are shown in Table 1. Among them, three patients had disease confined to the ileal while nine had ileocolitic involvement. Infliximab was used in five patients, and adalimumab in seven. One patient receiving each treatment underwent infliximab and one of adalimumab after surgery of ileocecal resection during their hospital stay. Nine patients received TPN (eight of whom were shifted to elemental diet therapy while still in hospital), and three patients received elemental diet therapy (in combination with peripheral parenteral nutrition in two patients). Seven patients were also treated with mesalazine and four with azathioprine.

As shown in Table 2, values for white blood cell (WBC) numbers, CDAI, and fat oxidation significantly decreased after treatment with anti-TNF-α antibodies, while serum albumin levels, PNI, RQ, and carbohydrate oxidation significantly increased. No significant changes in REE were noted after treatment ($p = 0.084$). The significant increases in RQ were supported by the findings of concomitant significant decreases in fat oxidation ($p<0.01$) and significant increases in carbohydrate oxidation ($p<0.01$).

We divided the patients into two groups according to REE at admission, with a cutoff of 25 kcal/kg/day. While CDAI decreased significantly in both groups ($p<0.05$) (Fig. 2), RQ significantly increased in the high-REE group ($p<0.05$) (Fig. 3). WBC numbers and C-reactive protein (CRP) levels also significantly decreased ($p<0.05$, respectively), while albumin significantly increased in patients in the high-REE group ($p<0.05$) (Table 3). Serum IL-6 levels were significantly decreased in the high-REE patients (Fig. 4). Platelet counts underwent a significant decrease in the high-REE group but remained in normal ranges before and after treatment.

**Discussion**

Recently introduced, infliximab and adalimumab are powerful tools for the treatment of CD. Nutritional therapy is also consid-
ered to be indispensable. The current study suggests that anti-TNF-α therapy has positive effects on both nutritional and inflammatory status, as demonstrated by the significant decrease in CDAI and increase in serum albumin levels, RQ, and PNI values after treatment. While the usefulness of PNI as a nutritional and inflammatory marker has been reported in patients with colon cancer,\(^{(17)}\) it has not yet been validated in CD patients. Potential availability and feasibility to evaluate the clinical activity and nutritional status of CD seems to be interesting, and further studies should be performed to validate its utility.

The treatment-related increase in RQ levels in the high-REE group might be due to decreases in lipolysis and recovery from starvation state induced by calming down the inflammation. Findings concerning the effects of anti-TNF-α therapy on energy metabolism in CD patients are controversial. Wiese \textit{et al.}\(^{(22)}\) reported that RQ tended to increase after infliximab therapy \((p = 0.07)\), whereas no increase was detected in the REE value. In contrast, Steiner \textit{et al.}\(^{(23)}\) working with pediatric patients reported a significant reduction in RQ during parenteral nutrition after infliximab therapy. To our knowledge, ours is the first report demonstrating that RQ values are significantly increased after treatment with anti-TNF-α therapy in patients with active CD.

### Table 1. Characteristics of CD patients \((n = 12)\)

| Characteristics          | Pre-treatment | Post-treatment |
|--------------------------|--------------|---------------|
| Age (y)                  | 27 (24, 36)  | 27 (24, 36)   |
| Gender (male/female)     | 9/3          | 9/3           |
| BMI (kg/m\(^2\))        | 17.7 (16.6, 21.2) | 18.3 (17.1, 20.9) |
| Type of CD (ileal/ileocolic) | 3/9          | 3/9           |
| Anti-TNF-α (infliximab and adalimumab) | 5/7          | 5/7           |
| Nutritional therapy      | TPN (TPN shifted to ED therapy) | 9 (8)         |
| Elemental diet therapy (ED therapy in combination with PPN) | 3 (2)        | 3 (2)         |

CD, Crohn Disease; BMI, body mass index; TPN, total parenteral nutrition; ED, elemental diet; PPN, peripheral parenteral nutrition. Values are expressed as median (25% quartile, 75% quartile).

### Table 2. All values before and after treatment \((n = 12)\)

| Body weight | Pre- | Post- | p     |
|-------------|------|-------|-------|
| BMI (kg/m\(^2\)) | 17.7 (16.6, 21.2) | 18.3 (17.1, 20.9) | 0.265 |
| %IBW (%)    | 80.3 (75.6, 96.2) | 82.8 (77.8, 95.1) | 0.23  |
| %UBW (%)    | 86.8 (83.3, 97.0) | 89.6 (86.6, 95.4) | 0.213 |

Laboratory tests

| RBC (\(\times 10^4/mm^3\)) | Pre- | Post- | p     |
|-----------------------------|------|-------|-------|
| Hb (g/dL)                   | 11.3 (9.4, 11.9) | 11.6 (11.1, 12.0) | 0.1   |
| Ht (%)                      | 35.0 (28.2, 36.8) | 35.1 (33.7, 36.7) | 0.136 |
| WBC (\(\times 10^3/mm^3\)) | 6700 (6100, 8900) | 5000 (4000, 5700) | 0.041 |
| MCV (fl)                    | 85.3 (78.4, 86.7) | 87.7 (82.0, 89.0) | 0.117 |
| TLC (\(\times 10^3/mm^3\)) | 1530 (1134, 2089) | 1837 (1636, 2113) | 0.099 |
| Plt (\(\times 10^3/mm^3\)) | 438 (404, 496) | 311 (244, 345) | 0.062 |
| CRP (mg/dL)                 | 2.36 (1.07, 5.14) | 0.12 (0.04, 0.23) | 0.06  |
| Alb (g/dL)                  | 3.0 (2.8, 3.3) | 3.6 (3.5, 3.8) | 0.004 |

Index

| PNI | Pre- | Post- | p     |
|-----|------|-------|-------|
| 38.7 (34.6, 43.1) | 46.1 (45.7, 47.8) | 0.012 |

Energy metabolism

| REE (kcal/kg/day) | Pre- | Post- | p     |
|-------------------|------|-------|-------|
| 26.6 (23.4, 30.6) | 24.9 (21.8, 26.6) | 0.084 |
| RQ                | 0.82 (0.80, 0.85) | 0.86 (0.84, 0.95) | 0.003 |
| Fat oxidation (kcal/kg/day) | 14.7 (13.3, 16.9) | 9.4 (4.3, 12.2) | 0.002 |
| Carbohydrate oxidation (kcal/kg/day) | 8.7 (7.5, 14.8) | 13.2 (9.2, 21.5) | 0.008 |

Inflammatory cytokines

| TNF-α (pg/dL) | Pre- | Post- | p     |
|---------------|------|-------|-------|
| 2.1 (1.8, 2.5) | 2.2 (1.4, 3.8) | 0.185 |
| IL-6 (pg/dL)  | 10.7 (6.2, 14.7) | 3.0 (2.1, 4.1) | 0.091 |

BMI, body mass index; %IBW, % ideal body weight; %UBW, % usual body weight; RBC, red blood cell count; Hb, hemoglobin; Ht, hematocrit; WBC, white blood cell count; MCV, mean corpuscular volume; TLC, total lymphocyte count; Plt, platelets; CRP, C-reactive protein; Alb, albumin; CDAI, Crohn disease activity index; PNI, prognostic nutritional index; REE, resting energy expenditure; RQ, respiratory quotient; TNF-α, tumor necrosis factor α; IL-6, interleukin-6. Values are expressed as median (25% quartile, 75% quartile).
The reduced fat stores in CD patients can be explained by an increase in fat oxidation. Glucose oxidation may be inhibited by pro-inflammatory cytokines such as TNF-α and IL-6, and the principal metabolic substrate may shift from fat to carbohydrate oxidation after anti-TNF-α therapy. This suggests that RQ is a useful marker in the assessment of disease activity and the prediction of response to anti-TNF-α therapy.

The measurement of individual REE is essential for planning optimal nutritional treatment regimens in CD patients in order to prevent overfeeding and the resultant Refeeding syndrome. In the present study, REE values did not show significant change during anti-TNF-α treatment. Our observations are compatible with the findings of some recent reports. For example, Wiese et al. reported no significant changes in REE values after 6 weeks and 6 months of infliximab therapy in adult CD patients, and another study in pediatric patients found no significant changes in REE after 2 weeks of infliximab therapy. However, Kushner et al. reported that REE increased with increasing clinical disease activity. These conflicting findings may indicate a complicated energy status in patients with active disease, due to starvation from reduced dietary intake and superimposed hypermetabolic status associated with the inflammation.

In the high-REE group, serum IL-6 levels significantly decreased after anti-TNF-α therapy, but this was not observed in the low-REE group. This finding is compatible with the recent report that IL-6 is one of several factors contributing to the REE value and that serum IL-6 levels correlate with severity of malnutrition. These findings suggest that higher IL-6 levels before treatment can be used to predict efficacy of anti-TNF-α therapy and thereby improve nutritional status as well as inflammatory status.

TNF-α has been reported to be a strong inducer of IL-6 production in many cell types, suggesting that at least some of the elevation of serum IL-6 levels is dependent on TNF-α. TNF-α likely played a role in the elevation of serum IL-6 levels in the high-REE patients in the present study, and neutralization of TNF-α by anti-TNF-α antibodies may improve TNF-α-dependent IL-6 elevation and any part of the REE value that is IL-6-dependent.

In contrast, in the low-REE patients, IL-6 levels were not
Fig. 4. Comparison of changes in IL-6 levels with REE on admission (cutoff, 25 kcal/kg/day). Data are expressed as the median and inter-quartile ranges. IL-6, interleukin-6; REE, resting energy expenditure; ns, not significant.

References

1 Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010; 45: 9–16.
2 Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol 2012; 47: 1298–1307.
3 Andoh A, Imaeda H, Aomatsu T, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011; 46: 479–486.
4 Jeejeebhoy KN. The many faces of malnutrition in Crohn disease. Am J Clin Nutr 1998; 67: 819–820.
5 Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627–635.
6 Meckijian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology 1979; 77: 898–906.
7 Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: A randomized-controlled trial. Aliment Pharmacol Ther 2006; 24: 1333–1340.
8 Sasaki M, Johtatsu T, Kurihara M, et al. Energy metabolism in Japanese patients with Crohn’s disease. J Clin Biochem Nutr 2010; 46: 68–72.
9 Al-Jaouni R, Hébuterne X, Pouget I, Rampal P. Energy metabolism and substrate oxidation in patients with Crohn’s disease. Nutrition 2000; 16: 173–178.
10 Kushner RF, Schoeller DA. Resting and total energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 1991; 53: 161–165.
11 Schneeweiss B, Lochs H, Zauner C, et al. Energy and substrate metabolism in patients with active Crohn’s disease. J Nutr 1999; 129: 844–848.
12 Bantel H, Schulze-Osthoff K. TNF antagonists in IBD: novel antiinflammatory mechanisms beyond cytokine inhibition. Inflamm Bowel Dis 2013; 19: E51–E52.
13 Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12 (Suppl 1): S3–S9.
14 Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.
15 Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–333.
16 Harvey RF, Bradshaw MJ. Measuring Crohn’s disease activity. Lancet 1980; 1: 1134–1135.
17 Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastro-intestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 1984; 85: 1001–1005 (in Japanese).
18 Sasaki M, Okamoto H, Johtatsu T, et al. Resting energy expenditure in patients undergoing pylorus preserving pancreato-duodenectomy for bile duct cancer or pancreatic tumors. J Clin Biochem Nutr 2011; 48: 183–186.
19 Okamoto H, Sasaki M, Johtatsu T, et al. Resting energy expenditure and nutritional status in patients undergoing transhiatal esophagectomy for esophageal cancer. J Clin Biochem Nutr 2011; 49: 169–173.
20 Sasaki M, Johtatsu T, Kurihara M, et al. Energy expenditure in Japanese patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr 2010; 47: 32–36.
21 Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1–9.
22 Wiese D, Lashner B, Seidner D. Measurement of nutrition status in Crohn’s disease patients receiving infliximab therapy. Nutr Clin Pract 2008; 23: 551–556.
23 Steiner SJ, Pfiefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn’s disease. Pediatr Res 2008; 64: 673–676.
24 Jin MB, Shimahara Y, Yamaguchi T, et al. The effect of a bolus injection of TNF-α and IL-1 β on hepatic energy metabolism in rats. J Surg Res 1995; 58: 509–515.
25 Kroder G, Bossenmaier B, Kellerm B, et al. Tumor necrosis factor-α and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996; 97: 1471–1477.
26 Fernandez A, Brotin I, Marin-Jimenez J, Menchén L. Refeeding syndrome in a patient with Crohn’s disease. J Clin Gastroenterol 2008; 42: 430–431.
27 Steiner SJ, Pfiefferkorn MD, Fitzgerald JF, Denne SC. Protein and energy metabolism response to the initial dose of infliximab in children with Crohn’s disease. Inflamm Bowel Dis 2007; 13: 737–744.
28 Bynin K, Herrick AL, Carlson GL, Hopkins SJ. The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis. J Inflamm Res 2011; 4: 61–66.
29 Barber MD, McMillan DC, Wallace AM, Ross JA, Preston T, Fearon KCH. The response of leptin, interleukin-6 and fat oxidation to feeding in weight-lossing patients with pancreatic cancer. Br J Cancer 2004; 90: 1129–1132.

No potential interests of conflict were disclosed.
30 Hata K, Andoh A, Shimada M, et al. IL-17 stimulates inflammatory responses via NF-κB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1035–G1044.

31 Shimada M, Andoh A, Hata K, et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 2002; 168: 861–868.

32 Ikeda S, Saito H, Fukatsu K, et al. Dietary restriction impairs neutrophil exudation by reducing CD11b/CD18 expression and chemokine production. Arch Surg 2001; 136: 297–304.

33 Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477–481.